Wegovy vs Saxenda: Switching Between Them, What Patients and Clinicians Need to Know

How Do Wegovy and Saxenda Compare on Weight Loss?

Both drugs activate the GLP-1 receptor to reduce appetite and slow gastric emptying, but their clinical results differ substantially. STEP-1 (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo [1]. The SCALE Obesity and Prediabetes trial (N=3,731) showed liraglutide 3 mg achieved 8.0% mean weight loss at 56 weeks versus 2.6% with placebo [2]. That is roughly a 7-percentage-point gap in favor of semaglutide, though the trials enrolled different populations and ran for different durations.

Why the Efficacy Gap Exists

Semaglutide's molecular structure includes a C18 fatty-diacid chain that extends its plasma half-life to approximately 165 hours (about 7 days), enabling once-weekly dosing and sustained GLP-1 receptor occupancy [3]. Liraglutide carries a C16 fatty-acid modification that yields a half-life of roughly 13 hours, requiring daily injection to maintain receptor activation [4]. Longer receptor engagement may drive deeper appetite suppression and greater cumulative caloric deficit, which could explain part of the efficacy difference.

What an Indirect Comparison Shows

A 2022 network meta-analysis published in Obesity Reviews (Shi et al., N=28 trials) ranked semaglutide 2.4 mg as the most effective approved pharmacotherapy for weight loss among GLP-1 agents, with a mean difference of approximately 6.3 kg more weight lost compared with liraglutide 3 mg [5]. No direct randomized head-to-head trial of these two specific doses in people with obesity (without type 2 diabetes) has been published as of January 2025.

Responder Rates

In STEP-1, 86.4% of participants on semaglutide lost at least 5% of body weight, and 69.1% lost at least 10% [1]. In SCALE, 63.2% of liraglutide patients lost at least 5% and 33.1% lost at least 10% [2]. Patients who need 10% or more weight loss for a clinical goal (joint offloading, fertility optimization, glycemic control) are considerably more likely to reach that threshold with semaglutide.

Dosing Schedules and Titration Timelines

Getting the titration right matters as much as choosing the drug. Both agents require a gradual dose escalation to reduce nausea, vomiting, and gastrointestinal discomfort.

Wegovy Titration

Wegovy follows a five-step escalation schedule [6]:

• Weeks 1 to 4: 0.25 mg once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9 to 12: 1.0 mg once weekly
• Weeks 13 to 16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

Reaching the full maintenance dose takes 16 weeks minimum. The FDA label permits extending any step by 4 additional weeks if tolerability is a concern [6].

Saxenda Titration

Saxenda escalates over 5 weeks [7]:

• Week 1: 0.6 mg once daily
• Week 2: 1.2 mg once daily
• Week 3: 1.8 mg once daily
• Week 4: 2.4 mg once daily
• Week 5 onward: 3.0 mg once daily (maintenance)

Patients reach the maintenance dose in as little as 4 to 5 weeks. That faster ramp can be an advantage for patients who need quicker therapeutic onset, though gastrointestinal side effects may be more pronounced during that shorter window.

Side-Effect Profiles: Similarities and Key Differences

The adverse-event profile of these two drugs overlaps substantially because they share a receptor target. Both cause predominantly gastrointestinal effects, and both carry the same class warnings.

Shared GI Effects

Nausea is the most frequently reported side effect with both agents. In STEP-1, nausea occurred in 44.2% of semaglutide participants versus 16.0% with placebo [1]. In SCALE, nausea affected 39.3% of liraglutide participants versus 13.8% with placebo [2]. Vomiting, diarrhea, and constipation appear at similar rates across both trials, and most GI events are mild to moderate and time-limited, peaking during escalation phases.

Injection-Site Reactions

Liraglutide requires daily subcutaneous injection, so injection-site reactions (erythema, nodules, bruising) accumulate over more injection events. Semaglutide's once-weekly schedule means fewer total punctures per year (52 vs 365), which may reduce cumulative local tissue trauma, though both drugs are generally well tolerated at the injection site [6, 7].

Class Warnings That Apply to Both

Both drugs carry FDA boxed warnings about thyroid C-cell tumors observed in rodent studies, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [6, 7]. Neither drug should be used in pregnancy.

Pancreatitis is listed as a warning for both. Patients with a history of pancreatitis should discuss the risk-benefit balance with their prescriber before starting either agent [6, 7].

Switching from Saxenda to Wegovy: A Clinical Protocol

Switching from liraglutide 3 mg to semaglutide 2.4 mg is the more common direction, typically because a patient is not meeting weight-loss goals on Saxenda, because Wegovy has become accessible (insurance, cost assistance, supply), or because the patient prefers weekly over daily injection.

Is a Washout Period Required?

No published randomized trial defines a mandatory washout period for this specific switch. Given liraglutide's half-life of approximately 13 hours, it is pharmacologically cleared within 2 to 3 days of the last dose [4]. Most clinical protocols used in practice stop liraglutide on Day 1 and begin semaglutide titration within 3 to 7 days, though individual clinicians may wait up to 2 weeks if GI symptoms have been severe.

The HealthRX clinical team uses the following decision framework for Saxenda-to-Wegovy transitions:

1. Stop liraglutide on the planned transition date.
2. Wait 3 to 7 days (or up to 14 days if GI intolerance was significant on liraglutide).
3. Begin semaglutide at the Week 1 starting dose of 0.25 mg once weekly regardless of the liraglutide dose the patient was on.
4. Proceed through the full 16-week Wegovy titration schedule.
5. Do not attempt to "fast-track" the semaglutide escalation because prior GLP-1 exposure does not reduce the risk of semaglutide-specific GI events at higher doses.

Managing GI Symptoms During the Switch

Some patients experience a transient increase in nausea during the first 2 to 4 weeks of semaglutide, even if they tolerated liraglutide well. Starting semaglutide at 0.25 mg and adhering to the standard titration schedule is the single most reliable mitigation strategy. Anti-nausea medications such as ondansetron 4 mg as needed may be prescribed during the escalation window if clinically appropriate.

Switching from Wegovy to Saxenda: When and How

This direction is less common but occurs when semaglutide is unavailable due to supply constraints, when a patient loses insurance coverage for Wegovy, or when a patient cannot tolerate semaglutide's side effects.

Washout Before Starting Saxenda

Semaglutide's long half-life of approximately 7 days means it persists in circulation for 5 to 7 weeks after the last dose [3]. Starting liraglutide too soon after stopping semaglutide adds a second GLP-1 agent on top of residual semaglutide exposure, which may intensify GI effects without clear efficacy benefit. A waiting period of at least 1 week after the last semaglutide injection before beginning liraglutide is a reasonable minimum; some clinicians prefer 2 to 4 weeks for patients who were on the 2.4 mg maintenance dose.

Retitration Is Always Required

Patients switching from Wegovy to Saxenda must begin Saxenda at the 0.6 mg/day starting dose and titrate up over 5 weeks to 3.0 mg/day. Beginning at a higher dose because the patient "was already on a GLP-1" risks significant GI toxicity and is not supported by the Saxenda prescribing information [7].

Weight Regain After the Switch

Patients should be counseled that switching from semaglutide 2.4 mg to liraglutide 3 mg may result in partial weight regain. The STEP-4 trial (N=803) demonstrated that discontinuing semaglutide after 20 weeks led to a mean weight regain of 6.9 percentage points over the subsequent 48 weeks [8]. While continuing on liraglutide maintains some GLP-1 activity, its lower efficacy compared with semaglutide means patients may not fully preserve the weight loss achieved on Wegovy.

Cardiovascular Outcomes: SELECT vs. LEADER

Weight loss alone does not capture the full clinical picture. Cardiovascular outcome data now differentiate these agents in important ways.

Semaglutide: SELECT Trial (2023)

The SELECT trial (N=17,604) enrolled adults with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide 2.4 mg reduced the rate of major adverse cardiovascular events (MACE: cardiovascular death, nonfatal MI, nonfatal stroke) by 20% versus placebo (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) over a mean follow-up of 39.8 months [9]. This was the first cardiovascular outcome trial to show MACE reduction for a GLP-1 agonist in a non-diabetic obesity population.

Liraglutide: LEADER Trial (2016)

The LEADER trial (N=9,340) evaluated liraglutide 1.8 mg (the diabetes dose, not the obesity dose of 3 mg) in patients with type 2 diabetes at high cardiovascular risk. Liraglutide reduced the composite MACE outcome by 13% versus placebo (HR 0.87; 95% CI 0.78 to 0.97; P=0.01 for superiority) [10]. No dedicated cardiovascular outcome trial for liraglutide 3 mg in obesity without diabetes has reported results.

The American Diabetes Association 2024 Standards of Care state: "For patients with type 2 diabetes and established CVD or high CVD risk, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended" [11]. Semaglutide now carries cardiovascular benefit data in people with obesity who do not have diabetes, which liraglutide at the 3 mg dose does not.

Insurance Coverage, Cost, and Practical Access

Cost is frequently the deciding factor in which drug a patient uses or continues.

List Prices and Assistance Programs

Wegovy's list price is approximately $1,349 per month as of late 2024. Saxenda's list price is approximately $1,539 per month. Both manufacturers offer savings programs: Novo Nordisk's Wegovy savings card can reduce out-of-pocket cost to $0 for eligible commercially insured patients, and the Saxenda savings offer similarly can reduce copays. Medicare Part D does not cover weight-loss drugs under current law for either agent, though SELECT trial data have prompted ongoing policy discussions.

Supply Constraints

Semaglutide 2.4 mg has experienced intermittent supply shortages since 2022. When Wegovy is unavailable, transitioning a patient to Saxenda (or to compounded semaglutide, pending FDA status) may be a temporary clinical decision. Patients in this situation should be counseled that the switch is a bridge strategy and that returning to semaglutide when available is generally the higher-efficacy option.

Who Should Choose Wegovy, Who Should Choose Saxenda

No single drug is right for every patient. The choice depends on efficacy goals, cardiovascular risk, injection preference, cost, and tolerability history.

Wegovy Is Generally Preferred When

• The patient needs 10% or greater weight loss (69.1% of STEP-1 participants achieved this on semaglutide vs 33.1% on liraglutide in SCALE) [1, 2].
• The patient has established cardiovascular disease or high CVD risk (SELECT data support MACE reduction) [9].
• The patient finds daily injection burdensome.
• Prior Saxenda use produced inadequate weight loss despite reaching the 3 mg maintenance dose.

Saxenda May Be Preferred When

• Wegovy is unavailable or unaffordable after assistance programs are exhausted.
• The patient has a specific clinical reason to avoid semaglutide (such as a known intolerance from a previous semaglutide formulation used for type 2 diabetes).
• A faster titration to maintenance dose is clinically desirable (5 weeks for Saxenda vs 16 weeks for Wegovy).
• The patient is already stable and responding well on liraglutide and there is no compelling reason to switch.

Monitoring Parameters During and After a Switch

Regardless of direction, a switch between GLP-1 agents warrants clinical follow-up.

Recommended monitoring during any GLP-1-to-GLP-1 switch:

• Body weight at 4 weeks, 8 weeks, and 16 weeks after starting the new agent.
• Gastrointestinal symptom assessment at each visit (nausea, vomiting, constipation severity using a validated scale).
• Heart rate (both drugs modestly increase resting heart rate by 2 to 3 bpm on average; clinically significant in patients with baseline tachycardia) [6, 7].
• HbA1c and fasting glucose in patients with prediabetes or type 2 diabetes at the 12-week mark.
• Gallbladder function if the patient reports right upper-quadrant pain (both drugs are associated with increased cholelithiasis risk; in STEP-1, cholelithiasis occurred in 2.6% of semaglutide vs 1.2% of placebo participants) [1].

The Endocrine Society 2015 Clinical Practice Guideline on pharmacological management of obesity recommends reassessing treatment response at 16 weeks: if a patient has not lost at least 4% of body weight, the prescriber should consider switching, increasing the dose where possible, or adding adjunct therapy [12].